scholarly journals Neprilysin inhibition does not alter dynamic of proenkephalin‐A 119‐159 and pro‐substance P in heart failure

2021 ◽  
Author(s):  
Henrike Arfsten ◽  
Georg Goliasch ◽  
Philipp E. Bartko ◽  
Suriya Prausmüller ◽  
Georg Spinka ◽  
...  
Keyword(s):  
Heart Failure ◽  
Substance P ◽  
Neprilysin Inhibition ◽  
Proenkephalin A

scholarly journals P787Angiotensin-neprilysin inhibition further reverses cardiac remodeling as compared to angiotensin inhibition in reduced heart failure patients

EP Europace ◽  
2018 ◽  
Vol 20 (suppl_1) ◽  
pp. i139-i139 ◽  
Author(s):  
C De Diego ◽  
L Gonzalez-Torres ◽  
E R Centurion ◽  
G De Lara ◽  
M Macias
Keyword(s):  
Heart Failure ◽  
Cardiac Remodeling ◽  
Heart Failure Patients ◽  
Neprilysin Inhibition

scholarly journals Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure

2019 ◽  
Vol 65 (10) ◽  
pp. 1239-1247 ◽  
Author(s):  
Evgeniya E Feygina ◽  
Marina M Artemieva ◽  
Alexander B Postnikov ◽  
Natalia N Tamm ◽  
Marina N Bloshchitsyna ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ring Opening ◽  
Active Form ◽  
Cross Reactivity ◽  
Plasma Samples ◽  
Time Points ◽  
Positive Effects ◽  
Edta Plasma ◽  
Neprilysin Inhibition ◽  
Nep Inhibition

Abstract BACKGROUND Entresto™ is a new heart failure (HF) therapy that includes the neprilysin (NEP) inhibitor sacubitril. One of the NEP substrates is B-type natriuretic peptide (BNP); its augmentation by NEP inhibition is considered as a possible mechanism for the positive effects of Entresto. We hypothesized that the circulating products of BNP proteolysis by NEP might reflect NEP impact on the metabolism of active BNP. We suggest that NEP-based BNP cleavage at position 17–18 results in BNP ring opening and formation of a novel epitope with C-terminal Arg-17 (BNP-neo17 form). In this study, we use a specific immunoassay to explore BNP-neo17 in a rat model and HF patient plasma. METHODS We injected BNP into rats, with or without NEP inhibition with sacubitril. BNP-neo17 in plasma samples at different time points was measured with a specific immunoassay with neglectable cross-reactivity to intact forms. BNP-neo17 and total BNP were measured in EDTA plasma samples of HF patients. RESULTS BNP-neo17 generation in rat circulation was prevented by NEP inhibition. The maximum 13.2-fold difference in BNP-neo17 concentrations with and without sacubitril was observed at 2 min after injection. BNP-neo17 concentrations in 32 HF patient EDTA plasma samples ranged from 0 to 37 pg/mL (median, 5.4; interquartile range, 0–9.1). BNP-neo17/total BNP had no correlation with total BNP concentration (with r = −0.175, P = 0.680) and showed variability among individuals. CONCLUSIONS BNP-neo17 formation is NEP dependent. Considering that BNP-neo17 is generated from the active form of BNP by NEP, we speculate that BNP-neo17 may reflect both the NEP activity and natriuretic potential and serve for HF therapy guidance.

scholarly journals Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists

2020 ◽  
Vol 76 (9) ◽  
pp. 1034-1048 ◽  
Author(s):  
Andrew P. Ambrosy ◽  
Eugene Braunwald ◽  
David A. Morrow ◽  
Adam D. DeVore ◽  
Kevin McCague ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renin Angiotensin System ◽  
Angiotensin Receptor ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
History Of ◽  
Neprilysin Inhibition

Neprilysin Inhibition and the Treatment of Heart Failure

2017 ◽  
Vol 25 (6) ◽  
pp. 315-320 ◽  
Author(s):  
Nicholas Bartell ◽  
William H. Frishman
Keyword(s):  
Heart Failure ◽  
Neprilysin Inhibition
Sign in / Sign up

Export Citation Format

Share Document